{
  "id": 16650843,
  "title": "Corxel, an obesity drugmaker, to go public via SPAC deal",
  "url": "https://urgent.news/2026/10/26/corxel-an-obesity-drugmaker-to-go-public-via-spac-deal",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-26T19:17:00.000Z",
  "source": {
    "name": "BioPharma Dive",
    "slug": "biopharma-dive",
    "url": "https://www.biopharmadive.com/news/corxel-pharmaceuticals-spac-public-obesity-drugs/872772/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Armed with a $300 million financing and two GLP-1 and amylin-targeting medicines, Corxel is set to become the latest weight loss-focused company to join the public markets.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Endpoints News",
        "title": "Corxel to take oral GLP-1 public in the US via SPAC",
        "url": "https://urgent.news/2026/10/26/corxel-to-take-oral-glp-1-public-in-the-us-via-spac",
        "published": "2026-10-26T13:14:17.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}